TD Cowen analyst Tyler Van Buren maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report) yesterday. The company’s shares ...

Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

The fund outperformed its benchmark and peers for the final quarter and full year 2024, driven by positive stock selection.

Jones Financial Companies Lllp increased its stake in Regeneron Pharmaceuticals by 107.7% in Q4, now holding 812 shares.

The US pharmaceutical sector is experiencing a distinct trend never seen before with large American pharma companies continually looking for medicines in China.

This writer digs into the CRISPR gene-editing space, asking whether one particular penny stock is worth taking a punt on in his ISA.

Mutual of America Capital Management LLC reduced its stake in Regeneron Pharmaceuticals by 3.4%, selling 457 shares in Q4.

While Bayer’s consumer and crop science divisions continued to slide—both in the fourth quarter and in 2024 overall—the ...

We recently published a list of 10 Worst Performing Large Cap Stocks to Buy According to Analysts. In this article, we are ...

Rare Disease Day, an annual gathering hosted by the FDA and National Institutes of Health, was postponed. Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a ...

Intellia Therapeutics, a leading clinical-stage gene editing company, has released its financial results for the fourth ...